LEADER 01463nam  2200421   450 
001 9910704967503321
005 20131118105056.0
035   $a(CKB)5470000002446069
035   $a(OCoLC)863154300
035   $a(EXLCZ)995470000002446069
100   $a20131118d2013      ua             0
101 0 $aeng
135   $aurmn|||||||||
181   $2rdacontent
182   $2rdamedia
183   $2rdacarrier
200 10$aElectronic drug labeling $eno consensus on the advantages and disadvantages of its exclusive use : report to congressional committees
210  1$a[Washington, D.C.] :$cUnited States Government Accountability Office,$d2013.
215   $a1 online resource (ii, 20 pages)
300   $aTitle from title screen (viewed Nov. 7, 2013).
300   $a"July 2013."
300   $a"GAO-13-592."
320   $aIncludes bibliographical references.
517   $aElectronic drug labeling 
606   $aDrugs$xLabeling$xGovernment policy$zUnited States
606   $aElectronic records$xGovernment policy$zUnited States
606   $aPublic health$zUnited States
606   $aPharmaceutical industry$zUnited States
615  0$aDrugs$xLabeling$xGovernment policy
615  0$aElectronic records$xGovernment policy
615  0$aPublic health
615  0$aPharmaceutical industry
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910704967503321
996   $aElectronic drug labeling$93522150
997   $aUNINA